Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02616302
Other study ID # TAK-390MR_204
Secondary ID 2014-004506-15U1
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 20, 2023
Est. completion date January 20, 2025

Study information

Verified date March 2023
Source Takeda
Contact Takeda Contact
Phone +1-877-825-3327
Email medinfoUS@takeda.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main aims of the study are to see the - side effects of Dexlansoprazole treatment - effectiveness of Dexlansoprazole treatment in children having symptomatic nonerosive gastroesophageal reflux disease (GERD). Participants will take Dexlansoprazole by mouth once daily for 12 weeks


Description:

The drug being tested in this study is called dexlansoprazole. Dexlansoprazole is being tested to treat children aged 2 to 11 years who have nonerosive GERD. This study will look at the effectiveness and side effects of three different doses of dexlansoprazole in children with GERD. The study will enroll approximately 70 patients. Participants weighing ≤30 kg will be randomly assigned (by chance, like flipping a coin) to receive dexlansoprazole 15 or 30 mg, and participants who weigh >30 kg will be randomized to receive dexlansoprazole 30 or 60 mg. All participants will be asked to take one capsule at the same time each day throughout the study. Parents/caregivers for participants ages 2 to 8 and participants ages 9 to 11 will be asked to record any time they have heartburn symptoms in an electronic diary. This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 16 weeks, which includes up to 4 weeks to screen for the study. Participants will make multiple visits to the clinic, plus a final phone call 5 to 10 days after last dose of study drug for a follow-up assessment.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date January 20, 2025
Est. primary completion date January 20, 2025
Accepts healthy volunteers No
Gender All
Age group 2 Years to 11 Years
Eligibility Inclusion Criteria: 1. In the opinion of the investigator, the participant (as age appropriate) and/or parent(s)/legal guardian is capable of understanding and complying with protocol requirements. 2. Prior to any study-specific procedures being performed, the appropriate informed consent and the assent form(s) (as applicable) must be signed and dated by parent(s) or legal guardian and by the participant respectively, if appropriate. 3. Has a medical history of symptoms of GERD for at least 3 months prior to Screening. 4. Has a medical history of at least 1 failed attempted withdrawal of prior proton pump inhibitor (PPI)/acid-suppressive therapy and a return of symptoms upon withdrawal. 5. Has met the eDiary qualification criteria as assessed by the PGSDD, defined as hurting or burning in the stomach, chest, or throat on at least 3 of any 7 consecutive days during the Screening Period. 6. Has no evidence of erosive esophagitis (EE) according to the Los Angeles (LA) Classification of Esophagitis and, in the investigator's clinical judgment, the symptoms are suggestive of acid-related disease. A 24-hour pH-metry (with or without impedance) may be performed during Screening or within 6 months prior to Screening for similar symptoms as those identified during Screening if, in the investigator's judgment, this procedure would aid in the determination of whether the participant's symptoms are acid-related. An endoscopy performed within 1 week prior to signing screening informed consent and assent form (as applicable) is an acceptable replacement for the screening endoscopy if GERD is documented by the LA classification scale criterion, protocol-required biopsies were collected and endoscopic pictures were obtained. 7. Is male or female and age 2 to 11 years, inclusive, at the time of screening informed consent. Exclusion Criteria: 1. Has evidence of cardiovascular, pulmonary, central nervous system, hepatic, hematopoietic, renal, or metabolic disorder, severe allergy, asthma, or allergic skin rash that suggests any uncontrolled, clinically significant underlying disease or condition (other than the disease being studied), which may impact the ability of the participant to participate or potentially confound the study results. 2. Has a coexisting disease affecting the esophagus (eg, esophageal varices, scleroderma, viral or fungal infection, or esophageal stricture), history of radiation therapy or cryotherapy to the esophagus, caustic or physiochemical trauma such as sclerotherapy to the esophagus. 3. Has any findings in his/her medical history, physical examination, or safety clinical laboratory tests giving reasonable suspicion of underlying disease that might interfere with the conduct of the trial. 4. Has a history of hypersensitivity or allergies to dexlansoprazole or any component of the formulation of dexlansoprazole capsules, or any PPI (including lansoprazole, omeprazole, rabeprazole, pantoprazole, or esomeprazole) or antacids. 5. Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study evaluation period. 6. Has a condition that may require inpatient surgery during the course of the study. 7. Has known history of Barrett's esophagus with dysplastic changes in the esophagus. 8. Has a known history of eosinophilic esophagitis (EoE) or endoscopic or histologic findings suggestive of EoE (>=15 eosinophils per high-powered field [HPF]) 9. Has history of celiac disease, tests positive for tissue transglutaminase (tTG), antibody or confirmed disease by histology. 10. Has history of inflammatory bowel disease, or irritable bowel syndrome. 11. Has active gastric or duodenal ulcers within 4 weeks prior to Day -1. If present >4 weeks prior to Day -1, ulcers must not be present upon screening endoscopy. 12. Requires dilatation of esophageal strictures and/or strictures preventing passage of the endoscope during the screening endoscopy. Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter) is acceptable. 13. A female participant who has reached menarche by Day -1. 14. Is known to be positive for the human immunodeficiency virus (HIV). 15. Has current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition. 16. Has a history of gastric, duodenal, or esophageal surgery except simple oversew of an ulcer. A history of gastric tube and/or percutaneous endoscopic gastrostomy (PEG) placement is allowed. 17. Had an acute upper gastrointestinal hemorrhage within 4 weeks prior to endoscopy. 18. Has donated or lost >10% of the total blood volume, undergone plasmapheresis, or has had a transfusion of any blood product within 90 days prior to the first dose of study drug. 19. Has a known history of alcohol abuse or illegal drug use within the past 12 months prior to the first dose of study drug. 20. Has any screening abnormal laboratory value that suggests a clinically significant underlying disease or condition that may prevent the participant from entering the study; or the participant has: creatinine >1.5 mg/dL, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >2 times the upper limit of normal (×ULN), or total bilirubin >2.0 mg/dL with AST/ALT elevated above the limits of normal values. 21. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study or may consent and assent (as applicable) under duress. Students of the institution/research facility who are under the supervision of, or in a subordinate role to, the investigator are also ineligible. 22. The participant, in the opinion of the investigator, is unlikely to comply with the protocol or is unsuitable for any other reason. 23. Has participated in another clinical study (not including screening for Study TAK-390MR_205 [NCT02615184]) and/or has received any investigational compound within 30 days prior to Screening.

Study Design


Intervention

Drug:
Dexlansoprazole
Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules

Locations

Country Name City State
Canada Women and Children's Health Research Institute Edmonton Alberta
Canada London Health Sciences Centre (LHSC) - Children's Hospital London Ontario
Colombia Hospital Universitario San Ignacio Bogota
Colombia Centro Medico Imbanaco de Cali S.A Cali
Colombia Fundacion Valle del Lili Cali
Lithuania Hospital of Lithuanian University of Health Sciences Kauno Klinikos Kaunas
Lithuania Children's Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos, Public Institution Vilnius
Mexico Boca Clinical Trials Mexico SC Colonia Las Americas Distrito Federal
Mexico Inspirepharma S. de R.L. de C.V. Monterrey Nuevo Leon
Mexico El Cielo Medical Center Puebla
Mexico SMIQ S. de R.L. de C.V. Queretaro
Mexico Clinical Research Institute S.C. Tlalnepantla Estado De Mexico
Poland In Vivo Osrodek Badan Klinicznych Bydgoszcz Kuyavia
Poland Uniwersytecki Szpital Dzieciecy w Krakowie Krakow Malopolskie
Poland Gabinet Lekarski Bartosz Korczowski Rzeszow Podkarpackie
Poland Instytut "Pomnik - Centrum Zdrowia Dziecka" Warszawa Masovia
United States Children's Center for Digestive Health Care, LLC Atlanta Georgia
United States University Hospitals Cleveland Medical Center Cleveland Ohio
United States Gastrointestinal Associates, PA Flowood Mississippi
United States GI for Kids Knoxville Tennessee
United States Envision Clinical Research, LLC Laredo Texas
United States D&H National Research Centers Miami Florida
United States University of South Alabama Mobile Alabama
United States Vanderbilt University Medical Center Nashville Tennessee
United States The Children's Hospital of The King's Daughters Norfolk Virginia
United States Measurable Outcome Research Oklahoma City Oklahoma
United States University of California San Francisco San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Canada,  Colombia,  Lithuania,  Mexico,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Days Without Hurting or Burning in the Stomach, Chest or Throat Over the 12 Weeks of Treatment Daily electronic diaries (eDiaries) will be completed which contain Pediatric Gastroesophageal Reflux Disease Symptom Daily Diaries (PGSDD) questionnaires that document presence or absence of hurting or burning in the stomach, chest or throat vomiting, regurgitation and trouble eating. Parents or caregivers of participants aged 2 to 8 years will complete the PGSDD (parent) in the eDiary for their child and participants aged 9 to 11 years will complete PGSDD (child) in the eDiary themselves. The eDiaries will be completed on a daily basis reflecting a continuous 24-hour period. Up to 12 weeks
Secondary Percentage of Days Without Hurting or Burning in the Stomach, Chest or Throat in Children Aged 9 to 11 Years Over the 12 Weeks of Treatment Daily eDiaries will be completed which contain PGSDD questionnaires that document presence or absence of hurting or burning in the stomach, chest or throat vomiting, regurgitation and trouble eating. Parents or caregivers of participants aged 2 to 8 years will complete the PGSDD (parent) in the eDiary for their child and participants aged 9 to 11 years will complete PGSDD (child) in the eDiary themselves. The eDiaries will be completed on a daily basis reflecting a continuous 24-hour period. Up to 12 weeks
Secondary Percentage of Days Without Hurting or Burning in the Stomach, Chest or Throat in Children Aged 2 to 8 Years Over the 12 Weeks of Treatment Daily eDiaries will be completed which contain PGSDD questionnaires that document presence or absence of hurting or burning in the stomach, chest or throat vomiting, regurgitation and trouble eating. Parents or caregivers of participants aged 2 to 8 years will complete the PGSDD (parent) in the eDiary for their child and participants aged 9 to 11 years will complete PGSDD (child) in the eDiary themselves. The eDiaries will be completed on a daily basis reflecting a continuous 24-hour period. Up to 12 weeks
Secondary Percentage of Days Without Vomiting Over the 12 Weeks of Treatment Daily eDiaries will be completed which contain PGSDD questionnaires that document presence or absence of hurting or burning in the stomach, chest or throat vomiting, regurgitation and trouble eating. Parents or caregivers of participants aged 2 to 8 years will complete the PGSDD (parent) in the eDiary for their child and participants aged 9 to 11 years will complete PGSDD (child) in the eDiary themselves. The eDiaries will be completed on a daily basis reflecting a continuous 24-hour period. Up to 12 weeks
Secondary Percentage of Days Food Did Not Come Up from Stomach to Mouth Over the 12 Weeks of Treatment Daily eDiaries will be completed which contain PGSDD questionnaires that document presence or absence of hurting or burning in the stomach, chest or throat vomiting, regurgitation and trouble eating. Parents or caregivers of participants aged 2 to 8 years will complete the PGSDD (parent) in the eDiary for their child and participants aged 9 to 11 years will complete PGSDD (child) in the eDiary themselves. The eDiaries will be completed on a daily basis reflecting a continuous 24-hour period. Up to 12 weeks
Secondary Percentage of Days Without Trouble Eating Over the 12 Weeks of Treatment Daily eDiaries will be completed which contain PGSDD questionnaires that document presence or absence of hurting or burning in the stomach, chest or throat vomiting, regurgitation and trouble eating. Parents or caregivers of participants aged 2 to 8 years will complete the PGSDD (parent) in the eDiary for their child and participants aged 9 to 11 years will complete PGSDD (child) in the eDiary themselves. The eDiaries will be completed on a daily basis reflecting a continuous 24-hour period. Up to 12 weeks
Secondary Difference of the Median Percentage of Days Without Hurting or Burning in the Stomach, Chest, or Throat Over the 12 Weeks of Treatment Between the High Dose and the low Dose Within Each Weight Strata Daily eDiaries will be completed which contain PGSDD questionnaires that document presence or absence of hurting or burning in the stomach, chest or throat vomiting, regurgitation and trouble eating. Parents or caregivers of participants aged 2 to 8 years will complete the PGSDD (parent) in the eDiary for their child and participants aged 9 to 11 years will complete PGSDD (child) in the eDiary themselves. The eDiaries will be completed on a daily basis reflecting a continuous 24-hour period. Up to 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03561883 - Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) Phase 3
Completed NCT02555852 - Proton Pump Inhibitors and Risk of Community-acquired Pneumonia N/A
Completed NCT01406210 - RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol N/A
Terminated NCT01327963 - Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study N/A
Completed NCT01570842 - Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury N/A
Completed NCT02141711 - TAK-438 - Safety, Blood Levels & Effects of Repeated Doses Phase 1
Terminated NCT00587275 - Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI Phase 2
Completed NCT00228527 - Esomeprazole for Treatment of GERD in Pediatric Patients Phase 4
Completed NCT00261300 - Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708) Phase 3
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Completed NCT00795093 - Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US N/A
Completed NCT00394472 - Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients Phase 2
Completed NCT00574925 - Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Phase 4
Terminated NCT02749071 - An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux N/A
Recruiting NCT01129713 - Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE. Phase 1/Phase 2
Completed NCT00734747 - Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD) Phase 3
Completed NCT00312806 - Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341) Phase 3
Not yet recruiting NCT05579587 - Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
Recruiting NCT02366169 - Medigus Ultrasonic Surgical Endostapler (MUSE) Registry N/A
Completed NCT01374074 - Racial Disparity in Barrett's Esophagus N/A